A Look At Bausch + Lomb (NYSE:BLCO) Valuation As Glaucoma Pipeline Webinar Draws Fresh Attention

Simply Wall St.03-10

Bausch + Lomb (BLCO) is drawing fresh attention after announcing an upcoming R&D webinar focused on its glaucoma pipeline, including drug candidate BL1107 and the ELIOS minimally invasive glaucoma ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618345959?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155","is_english":true,"pubTime":"2026-03-10 21:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618345959","market":"nz","top_or_hot":-1,"title":"A Look At Bausch + Lomb (NYSE:BLCO) Valuation As Glaucoma Pipeline Webinar Draws Fresh Attention","media":"Simply Wall St.","content":"<div>\n<p>Bausch + Lomb (BLCO) is drawing fresh attention after announcing an upcoming R&D webinar focused on its glaucoma pipeline, including drug candidate BL1107 and the ELIOS minimally invasive glaucoma ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-blco/bausch-lomb/news/a-look-at-bausch-lomb-nyseblco-valuation-as-glaucoma-pipelin\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Bausch + Lomb (NYSE:BLCO) Valuation As Glaucoma Pipeline Webinar Draws Fresh Attention</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Bausch + Lomb (NYSE:BLCO) Valuation As Glaucoma Pipeline Webinar Draws Fresh Attention\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-10 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-blco/bausch-lomb/news/a-look-at-bausch-lomb-nyseblco-valuation-as-glaucoma-pipelin><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bausch + Lomb (BLCO) is drawing fresh attention after announcing an upcoming R&D webinar focused on its glaucoma pipeline, including drug candidate BL1107 and the ELIOS minimally invasive glaucoma ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-blco/bausch-lomb/news/a-look-at-bausch-lomb-nyseblco-valuation-as-glaucoma-pipelin\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NYSE","symbol_name":"纽交所","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-blco/bausch-lomb/news/a-look-at-bausch-lomb-nyseblco-valuation-as-glaucoma-pipelin","article_id":"2618345959","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-blco/bausch-lomb/news/a-look-at-bausch-lomb-nyseblco-valuation-as-glaucoma-pipelin","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618345959","pubTimestamp":1773148623,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Bausch + Lomb (BLCO) is drawing fresh attention after announcing an upcoming R&D webinar focused on its glaucoma pipeline, including drug candidate BL1107 and the ELIOS minimally invasive glaucoma surgery platform.\nSee our latest analysis for Bausch + Lomb.\nThe upcoming glaucoma webinar follows a mixed stretch for the stock, with a 1-day share price return of 0.94% and a 7-day share price decline of 6.46%. This sits alongside a 1-year total shareholder return of 8.30% and a 3-year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"NYSE":"纽交所","BK4198":"医疗保健用品","BLCO":"博士伦"},"translate_title":"看博士伦（纽约证券交易所股票代码：BLCO）青光眼管道网络研讨会的估值引起了新的关注","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NYSE":1.5,"BLCO":1.5},"content_text":"Bausch + Lomb (BLCO) is drawing fresh attention after announcing an upcoming R&D webinar focused on its glaucoma pipeline, including drug candidate BL1107 and the ELIOS minimally invasive glaucoma surgery platform. See our latest analysis for Bausch + Lomb. The upcoming glaucoma webinar follows a mixed stretch for the stock, with a 1-day share price return of 0.94% and a 7-day share price decline of 6.46%. This sits alongside a 1-year total shareholder return of 8.30% and a 3-year total shareholder return of 9.89%. These figures suggest modest momentum, while recent R&D and product news around LUMIFY and the glaucoma pipeline keep attention on longer term prospects and risk perceptions. If this glaucoma and eye health focus has your attention, it could be a good moment to look across the sector and see what stands out in our 32 healthcare AI stocks. With an intrinsic value estimate suggesting a sizeable discount and the stock trading only slightly below the average analyst target, the key question is whether BLCO is still overlooked or if the market is already pricing in future growth. AdvertisementMost Popular Narrative: 20% Undervalued Against the last close of $17.22, the most followed narrative pegs Bausch + Lomb's fair value at $17.25, implying only a modest gap between price and projected worth, but built on a detailed growth and margin story.  Disciplined execution under the Vision 27 financial excellence program, including SG&A mix optimization, manufacturing efficiencies and focused R&D spend on near to mid term launch assets, is expected to support adjusted EBITDA growth above sales growth and drive expanding net margins and earnings power.  Read the complete narrative. Curious what kind of revenue path and margin uplift are baked in to reach that fair value, and what profit multiple that implies years from now? The narrative lays out a full earnings ramp, the expected shift from losses to profits, and the valuation lens used to justify it. However, the key assumptions sit behind that headline number. Result: Fair Value of $17.25 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there is still a risk that earnings and margin expansion fall short of the analyst path, or that the assumed 31.7x P/E on 2028 earnings proves too rich. Find out about the key risks to this Bausch + Lomb narrative. Next Steps With mixed signals across valuation, margins and future earnings, how does this all sit with you today? It is worth looking through the full breakdown yourself and weighing both sides of the story, including the 3 key rewards and 1 important warning sign. Looking for more investment ideas? If you are serious about building a stronger portfolio, do not stop at one stock. Use the screeners below to spot other opportunities that might fit your style.  Target potential value candidates by scanning our list of 46 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect them yet. Strengthen your income focus by checking out 14 dividend fortresses, a set of companies offering 5%+ yields with an emphasis on resilience. Reduce portfolio stress by reviewing 63 resilient stocks with low risk scores, highlighting companies with lower risk scores that could help balance out more volatile holdings.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Bausch + Lomb might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618345959","isCrawlerRequest":true}